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ABStrACt
Carnitine palmitoyl transferase I (CPT1) catalyzes the transport of long-chain fatty acids into mitochondria for b-oxidation. A link between CPT1 and apoptosis has been suggested on the basis of several experimental data. Nevertheless, results are contradictory about the effective role of CPT1 in cell survival control and cancer development. Conversely, Fatty acid synthase (FAS) enzyme, required for the synthesis of fatty acids, is found over-expressed in tumors and inhibition of FAS triggers apoptosis in human cancer cells.
We have studied the tumor-specific modulation of CPT1 and FAS in human colorectal cancer (n = 11) and breast carcinomas (n = 24). CPT1 was significantly decreased in the cytoplasm of tumoral samples (p < 0.04), whereas FAS was increased (p < 0.04). A striking CPT1 nuclear localization was evident in the tumors (p < 0.04). In the nuclear environment the protein would modulate the levels of acetyl/acyl-CoA implicated in the regulation of gene transcription. At this purpose, we performed in vitro experiments using epithelial neoplastic (MCF-7, Caco-2, HepG2 cells) and non neoplastic cell lines (MCF-12F) confirming a nuclear localization of CPT1 protein exclusively in neoplastic cells. Moreover histone deacetylase (HDAC) activity showed significantly higher levels in nuclear extracts from neoplastic than from control cells. HDAC1 and CPT1 proteins coimmunoprecipitated in nuclear extracts from MCF-7 cells. The treatment with HDAC inhibitors such as trichostatin A and butyrate significantly decreased nuclear expression of CPT1 and its bond to HDAC1. We also identified the existence of CPT1A mRNA transcript variant 2 in MCF-7, beside to the classic isoform 1.
The peculiar localization of CPT1 in the nuclei of human carcinomas and the disclosed functional link between nuclear CPT1 and HDAC1 propose a new role of CPT1 in the histonic acetylation level of tumors.
introduCtion
Mitochondrial dysfunction contributes to a number of human disorders and may aid cancer progression. In particular, functional alteration of enzymes involved in the mitochondrial oxidative metabolism has been found during apoptosis and neoplastic transformation. [1] [2] [3] The altered metabolism of neoplasia would favor an increased cell survival, promoting the increase of tumor size and cancer aggressiveness. Biochemical studies have demonstrated that one of the multiple differences between tumoral cells and healthy counterparts consists in the metabolic pathway, the uptake of glucose and the glycolytic process. 4, 5 In fact, the overall metabolic demand on the neoplastic cell is significantly higher than most other tissues and the cancer cell depends more on glycolysis, even in the presence of available oxygen. 5 The glycolytic process would be mediated by the AMP-activated protein kinase (AMPK) that functions as a low energy checkpoint: in the neoplastic cells it would restore depleted ATP levels through fatty acid oxidation. 5 The reliance of tumor cells on glycolysis may be a potential means by which these cells evade programmed cell death. 6 Carnitine Palmitoyl transferase 1 (CPT1) resides at the outer mitochondrial membrane and is a site for intracellular regulation of fatty acid metabolism, transporting long-chain fatty acids into mitochondria for b-oxidation (together with CPT2 and Carnitine/ acyl-Carnitine Translocase). 7, 8 Two isoforms of CPT1 have been characterized, known as L-CPT1 (CPT1A) and M-CPT1 (CPT1B) in liver (L-) and muscle (M-) respectively, showing overlapping tissue specific expression. While CPT1B is expressed in skeletal muscle, heart, testis and adipose tissue, CPT1A has a more widespread distribution. 7
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A link between CPT1 and apoptosis has been suggested on the basis of several experimental data. It was demonstrated that CPT1 interacts with Bcl-2 protein, that regulates programmed cell death in several systems and it is also expressed at the outer mitochondrial membrane. [9] [10] [11] On the other hand, increased levels of Fatty acid synthase (FAS), the major enzyme required for the anabolic conversion of dietary carbohydrate to fatty acids, are found in a wide array of solid tumors [12] [13] [14] [15] and FAS inhibition triggers apoptosis in human cancer cells, 8 supporting the "metabolic oncogene" theory for FAS overexpression in cancer cells. 15, 16 Taking into account the remodulation of the metabolic pathway in the cancerous cells and the unclear role of CPT1 in cell survival control and cancer development, we analyzed the protein expression of CPT1 and FAS in human tumor tissues (n = 35) and healthy counterparts (n = 35). Here we show that CPT1 expression decreases in the cytoplasm of tumoral tissues, whereas FAS increases in the same human tumors. In contrast, a nuclear localization of CPT1 is evident in the tumoral tissues. CPT1 was previously described on the nuclear membrane, 17 but its specific function in this cell compartment has not been clarified yet. In the nuclear environment, the protein would modulate the levels of acetyl/acyl-CoA and carnitine, both of which have been implicated in the regulation of gene transcription. 18 Then, we performed in vitro experiments using epithelial neoplastic (MCF-7, Caco-2, HepG2) and non transformed (MCF-12F) cell lines.
Two transcript variants have been recently described for CPT1-L (CPT1A) isoform, named variant 1 and 2, corresponding to the mRNA sequences NM_001876 and NM_001031847, respectively. 19, 20 The variant 2 differs in the 3'UTR and codes for an isoform with a shorter C-terminus.
Immunocytochemical experiments confirm a peculiar nuclear localization of CPT1A protein in the neoplastic cells. Moreover, we identify the presence of the CPT1A transcript variant 2 in the same cells, beside to the classic isoform 1. 19 To better clarify the role of nuclear CPT1A we studied its correlation with the histone deacetylase (HDAC) protein complex in the same cells. The histone deacetylase (HDAC) activity is significantly higher in nuclear extracts from neoplastic cells, as compared to the HDAC activity detected in MCF-12F cells. Moreover, HDAC1 and CPT1 proteins coimmunoprecipitate in nuclear extracts from neoplastic cells.
Inhibitors of histone deacetylase activity (HDACI) such as trichostatin A and sodium-butyrate are able to cause multiple effects in cultured mammalian cells, including inhibition of proliferation and induction of apoptosis, via de-repression of genes involved in cell growth and apoptosis. 21, 22 The treatment with such HDACI significantly decreases both the nuclear expression of CPT1 and the HDAC1-CPT1 bond, in MCF-7 cells.
In vitro results match the histonic and not histonic acetylation status in the tumoral samples: the acetylation of histone H4 protein is much lower in the tumors analyzed, as compared with controls.
Here we identify a new role of CPT1 in cancer development, further than the physiological role in the transport of long-chain fatty acids into mitochondria. In fact, the presence of CPT1 in the nuclei of cancerous tissues and neoplastic cells and the disclosed functional link between CPT1 and HDAC1, show that CPT1 plays a role in the histone acetylation status of the tumors. As a consequence, it could be involved in the transcriptional regulation of specific genes related to cancer development. Hence, the nuclear form of CPT1 might represent a new highly specific target for more effective anti-cancer therapies.
MAtEriALS And MEthodS
Patient characteristics and tissue samples. Eleven colorectal adeno-carcinomas (CRC) and twenty four breast invasive ductal carcinomas (IDC) were collected in the authors' department, irrespectively of the clinical staging. Informed consent was obtained from all the patients included in the study. Ethical approval was obtained by the authors' institutional review board. The mean age of the patients at the time of surgery was 69 ± 5 and the male/female ratio was 2:6. Distant normal mucosa (NM, n = 11) and adenomas with low grade dysplasia (ALGD, n = 6) were collected and analyzed for the colorectal cases. Histological classification was carried out on H&E-stained slides. [23] [24] [25] Tissue arrays. Tissue arrays (TA) were performed for breast cancer cases. Three 0.6 mm 2 cores of breast cancer tissue were removed from representative tumor areas on each block identified by the pathologist (EB). These cores were used to construct recipient array blocks in triplicate. Each TA was composed of 12 infiltrating ductal carcinomas (IDC) (3G1; 6G2; 3G3), and non neoplastic breast tissues (NB, n = 12: 5 fibro-adenomas, 4 usual ductal hyperplasia or UDH, 3 adenosis) as controls. Adjacent normal breast tissue was occasionally present and evaluated in the IDC cores. If one or more core were uninformative because of loss or lack of tumor in core, then the scoring results were taken from the remaining core(s).
The tissue array was sectioned, stained with haematoxylin-eosin and received a final pathology review. For immunohistochemistry, the TA was cut in 5 mm sections and stained with appropriate antibodies and controls.
Immunohistochemistry (IHC) and immunocytochemistry (ICC). Serial four micron sections from formalin-fixed and paraffin embedded specimens were immunostained for CPT1A, FAS, acetyl-lysine and acetyl-histone-H4 following the streptoavidin-biotin method, as previously described. 26 In brief, sections were deparaffinezed and rehydrated in decreasing alcohol. Tissue antigen retrieval was performed in citrate buffer by microwave. Endogenous peroxidase activity was quenched with 0.03% hydrogen peroxide in absolute methanol, for 30 min at room temperature. The primary antibodies used were rabbit polyclonal anti-CPT1A anti-FAS antibodies (H95 raised against a recombinant protein, mapping near the aminoterminus of CPT1A and H300, Santa Cruz Biotechnology Inc. CA 95060, USA) validated for immunohistochemical analysis, in 1:650 and 1:50 dilution, respectively. Anti-acetyl-lysine rabbit serum and rabbit polyclonal anti-acetyl-histone H4 (Upstate, NY 12946) were diluted 1:400 and 1:75 respectively. Biotinylated goat anti-rabbit IgG (Dako A/S, Denmark) were used as secondary antibody. After washing, sections were treated with streptoavidin-peroxidase reagent (Dakopatts A\S, Denmark), incubated with diaminobenzidine (DAB) and lightly counterstained with hematoxylin. Slides were examined by two pathologists, unaware of the clinical data and molecular results. Tissue staining was semi-quantitatively graded for intensity as negative/weak: 0, moderate: 1 and strong: 2. FAS and cytoplasmic CPT1 was regarded as positive when moderate-to-strong granular cytoplasmic staining was Cancer Biology & Therapy 2007; Vol. 6 Issue 10 detected. 14, 15 Acetyl-lysine and acetyl-histone-H4 were deemed positive when moderate(1)-to-strong(2) immunostaining was present in cytoplasm and/or nuclei. For nuclear CPT1, positively stained cells were quantified as a percentage and assigned to one of three categories: 0-10% (Neg); 11-20% and >20% (Pos) ( Tables 1 and 2 ). For immunocytochemistry, MCF-7, MCF-12F, Caco-2 and HepG2 cells were plated in 4 wells/chamberslides at a concentration of 60.000 x cm 2 . After overnight culture, cells were treated or not with sodium butyrate at concentration 5 mM (Sigma-Aldrich S.r.l., I-20151 MI, Italy) or trichostatin A (BioVision Research Products, Mountain View, CA 94043 USA), at concentration 1 mM and 3 mM, for 24 h to inhibit cellular HDAC activity. At the end, growth medium was removed and cells were rinsed in phosphate-buffered saline (PBS) and fixed in formalin 10% solution (Sigma-Aldrich) for 5 min. Then, cells were permeablized with 0.5% Triton X-100 and 0.05% Tween-20 (Bio-Rad Laboratories, Munchen) in PBS. Incubation and dilution times of primary antibody (rabbit polyclonal anti-CPT1A), secondary antibody (biotinylated goat anti-rabbit IgG) and following reagents (streptoavidin-peroxidase) were the same chosen for IHC experiments. After washing, slides were incubated with diaminobenzidine (DAB) and counterstained with haematoxylin.
Statistical analysis. All values provided in the text and figures are means of three independent experiments ± standard deviations (SD). Mean values were compared using the two-tailed Student t-test, for independent samples. For FAS and cytoplasmic CPT1 immunostaining, statistical significance was calculated comparing intensity values (from 0 to 2) between different groups, e.g., FAS staining values in normal mucosae (NM) versus adenocarcinomas (CRC). Percent values of positively stained cells were compared between different groups, for CPT1 nuclear staining (see Results). Differences were considered statistically significant for p < 0.05.
Cell culture, chemicals and protein extracts preparation. MCF-7 (HTB-22), MCF-12F (CRL-10783), HepG2 (HB-8065) and Caco-2 (HTB-37) were purchased from American Type Culture Collection (ATCC) and grown in complete culture medium, according to condition suggested from ATCC, at 37˚C temperature with 95% humidified air, 5% CO-2. For HDAC experiments, 60.000 x cm 2 cells were plated in 25 cm 2 flasks. After overnight culture, cells (treated or not with sodium butyrate 5 mM for 24 hours) were trypsinized, washed in PBS and pelleted for protein extraction according to Dignam method, 27 modified as described by Pucci et al. 28 Briefly, nuclear and cytoplasmic fractions were separated by centrifugation in a microfuge at 10,000 rpm and stored at -80˚C. Protein content in nuclear and cytoplasmic extracts was determined in triplicate by Bradford assay (Bio-Rad Protein Assay, Bio-Rad Laboratories, Munchen).
Western blotting and immunoprecipitation. Cytoplasmic and nuclear protein extracts (10 mg) were boiled in SDS-PAGE loading buffer and separated by 10% SDS-PAGE. Proteins were transferred to a PVDF membrane (Hybond-P, Amersham-Pharmacia Biotech, England HP7 9NA) using an electroblotting apparatus. Membranes were stained with Ponceau S dye, to check for equal loading and homogeneous transfer and incubated for 1 h at RT with 3% skim milk (Difco Lab. Detroit, MI, USA) and 0.5%Tween 20 (USB, Cleveland, Ohio, USA). Primary antibody (rabbit polyclonal anti-CPT1A H95, Santa Cruz) was diluted 1:1000 in 1% BSA and incubated for 1 h at room temperature; samples were washed extensively with 0.5% Tween-20 in Tris buffered saline and diluted 1:8000 secondary antibody (anti-rabbit-HRP IgG, Santa Cruz Biotechnologies, Inc.) was added in 1%BSA, 1%milk, 0.5% Tween-20, for 45' at room temperature.
Filters were reprobed with anti-Sp1 mouse IgG1 monoclonal antibody (Sigma-Aldrich, Saint Louis, Missouri 63103 USA) to test purity of the extracts and with anti-b-actin mouse monoclonal antibody (Sigma-Aldrich, Saint Louis, Missouri 63103 USA) to normalize the cytoplasmic protein levels. Filters were washed and developed using an enhanced chemiluminescence system (ECL, Amersham-Pharmacia Biotech, Pharmacia Biotech, England HP7 9NA).
Immunoprecipitation assay (IP). Immunoprecipitation assay (IP).was performed on nuclear extracts from tumoral cells (MCF-7) treated and not with inhibitor of HDAC1 activity, sodium-butyrate. 
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Fifty micrograms of nuclear extracts were immunoprecipitated with anti-HDAC1. In brief, protein extracts were precleared incubating them with Protein A-Agarose (50% slurry) for 30 minutes at 4˚C with agitation. The Agarose was removed, then 4 mg of anti-HDAC1 mouse monoclonal antibody (Upstate, NY12946) was added overnight at 4˚C with rotation. IP negative control was performed without HDAC1 antibody. After incubation, Protein A-Agarose was added for one hour at 4˚C with rotation. At the end, supernatants containing unbound proteins were carefully removed and the IP complexes were washed in wash buffer (PBS, NaCl 0.5 M, and after in PBS alone). Each immunoprecipitate was electrophoresed on a 10% poliacrylamide gel. Gel was stained with Ponceau S-dye, blotted onto PVDF membrane, probed with anti-CPT1 and anti-HDAC1 and detected with ECL. Supernatant from HDAC1-IP samples, containing unbound protein fraction (ub) was also loaded onto poliacrylamide gel.
RT-PCR analysis of CPT1A transcript variants. Total RNA was isolated from MCF-7 and MCF12F cells cultured in T75 Flasks using Tri Reagent (Ambion, Inc.), according to the manufacturer's instructions. RNA quantification was performed using spectrophotometry. Reverse transcription of total RNA (1 mg each cell line) was performed with Gene Amp RNA PCR Kit (Applied BioSystems) using Random Examers as primers to cDNA synthesis. To amplify the cDNA for CPT1A transcript variants 1 (NM_001876) and 2 (NM_001031847) the following primers (Invitrogen) were used:
CPT1A1f 5'-ATTCTCATCGCTTTGGAAGG-3' and CPT1A1r 5'-AGACATCAGGGGAGACTTTA-3'; CPT1A2f 5'-GACAAAG TGGAAAGTCTCAG-3' and CPT1A2r 5'-TGTGTCAGGCACT GTTCTCA-3'. Amplification protocol was performed in a thermal cycler (Applied Biosystems) with 35 cycles at 60˚C. PCR products were 327bp for CPT1A1 and 163 bp for CPT1A2 transcript variants. cDNA for b2-Microglobulin housekeeping gene was amplified as control. Ethidium-bromide stained 2% agarose gel was run at 100V and picture of the gel was acquired by scanning system.
Histone deacetylase (HDAC) activity. Nuclear protein extracts obtained from MCF-7, Caco-2, HepG2 and MCF-12F cells were used to detect HDAC activity with a colorimetric assay kit (BioVision Research Products, Mountain View, CA 94043 USA). In brief, HDAC colorimetric substrate, which comprise an acetylated lysine side chain, was added with 50 mg of nuclear protein extracts to each well of a 96-well plate. A 2-ml volume of 1 mg/ml of the HDAC inhibitor trichostatin A was added to control well. Deacetylation of the substrate sensitized it, so that, following treatment with Lysine Developer produced a chromophore. Samples were analyzed using an ELISA plate reader at 405 nm.
rESuLtS
Fatty acid synthase expression in human tumors by IHC. FAS protein was significantly increased in the cytoplasm of the malignant tumors analyzed (tumors vs controls: p = 0.003) ( Table 1 ). Only 13% of tumors (5/35) displayed absence or weak staining in the cytoplasm of neoplastic cells, versus 80% of controls (28/35) . Further, strong (2+) specific staining was detected in the 43% of positive tumors (13/30) (Table 1 ). In particular, the 91% of colon carcinomas (10/11) displayed positive staining (1+, 2+), whereas almost the 100% of normal cases (10/11) displayed absence of specific staining (NM vs CRC: p = 0.003) (Fig. 1C-F) .
Expression of CPT1 in human tumors by IHC.
The same tumors were also evaluated for CPT1 protein expression. Corresponding sections of distant normal mucosa (n = 11) were used as controls for the colorectal patients, whereas non neoplastic breast samples (n = 24) were examined for the other cases.
The 63% of the tumoral tissues analyzed (22/35) displayed absent or weak cytoplasmic staining for CPT1, whereas normal samples displayed moderate(1)-to-strong(2) cytoplasmic staining in 72% of cases (tumors vs controls: p < 0.04) ( Table 1 ). The cytoplasmic staining showed the typical granular pattern due to the mitochondrial localization of CPT1. In particular, the colorectal carcinomas showed a significant decrease of cytoplasmic expression compared with both healthy colonic mucosae and adenomas analyzed (CRC vs NM: p = 0.001 and vs ALGD: p = 0.04). Colon adenomas displayed a protein localization and expression comparable to their normal counterparts (ALGD vs NM: p = 0.06).
Besides, 8/11 colorectal cancers (73%) and 22/24 breast cancers (92%) showed a speckled nuclear staining, with percentage >20% of positive cells in 7/30 cases (Table 1) . In Figure 2 , ductal infiltrating breast carcinoma and CRC tissues were compared to matched controls. The specific nuclear staining was evident in the cancerous samples ( Fig. 2A-H) .
In vitro experiments. CPT1A protein expression. Detection of CPT1A by immunocytochemical analysis (ICC) showed a marked nuclear staining beside to the cytoplasmic staining in epithelial neoplastic cell lines (MCF-7, Caco-2, HepG2) (Fig. 3A) . CPT1A nuclear signal varied in intensity through the cell cycle, showing the highest level in condensing chromosomes, as cells progress through mitosis (not shown). Conversely, MCF-12F no tumoral cells displayed a barely detectable staining in the cytoplasm (Fig. 3A) .
Cytoplasmic and nuclear protein extracts from MCF-7 and MCF-12F cells were analyzed for CPT1A expression by Western blot analysis. The CPT1A cytoplasmic expression was detected both in MCF-7 and in MCF-12F cells, whereas the nuclear expression was specific of neoplastic cells (Fig. 3B) .
Histone deacetylase (HDAC) activity. We also tested HDAC activity on nuclear extracts from neoplastic (MCF-7, Caco-2, HepG2) and control cells (MCF-12F). The HDAC activity was significantly higher in neoplastic cells, than in MCF-12F cells (Fig. 4) . Two different HDACI, such as sodium-butyrate and trichostatin A (TSA) 21 was effective to inhibit HDAC activity in these cells (not shown). Besides, both treatments with HDAC inhibitors TSA and sodium-butyrate were effective to strongly decrease CPT1 nuclear staining in neoplastic cells (Fig. 5A) .
Co-immunoprecipitation experiments. Tumoral cells (MCF-7) were treated or not with sodium-butyrate for 24 hours at the concentration 5 mM, able to inhibit HDAC1 activity. The nuclear proteins were extracted, immunoprecipitated with anti-HDAC1 antibody and loaded onto a denaturing poliacrylamide gel. The filter, immunoprobed with anti-CPT1A antibody, showed a coimmunoprecipitation band in nuclear extract from untreated MCF-7 cells. This specific band was strongly reduced after sodium-butyrate treatment (Fig. 5B) . The immunoprecipitation bands were normalized, reprobing the filter with anti-HDAC1 antibody (not shown). 
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CPT1A transcript variant expression. Two transcript variants have been described for CPT1-L (CPT1A) isoform, named variant 1 and 2, corresponding to the mRNA sequences NM_001876 and NM_001031847 respectively. 19, 20 To investigate whether the different localization of the CPT1A protein found in breast epithelial cells corresponded to a differential expression of the two transcripts, we performed an RT-PCR with primers specific for the two mRNA sequences (see Material and Methods).
As shown in Figure 6 , the transcript variant 1 was expressed in the same manner both in MCF-7 and MCF-12F cells, whereas the cDNA of transcript variant 2 was amplified just in the neoplastic cells. A semi-quantitative analysis of PCR reaction was feasible by additional amplification of cDNA for b2 microglobulin (B2M) housekeeping gene (Fig. 6) .
Expression of acetyl-lysine and acetyl-histone H4 in human tissues. The same colorectal tumors (n = 11) and invasive ductal breast carcinomas (n = 24) investigated for CPT1 expression, together with corresponding normal tissues were also analyzed for expression of acetyl-histone H4 protein and whole cell acetylation status, by IHC. A significant decrease of acetyl-histone H4 protein expression was evident in the tumoral tissues, as compared with normal counterparts (CRC vs NM: p = 0.02; IDC vs NB: p = 0.03, Table 2 ). The hypoacetylation at histone level could represent a known mechanism for transcriptional repression of tumor suppressor genes during carcinogenesis. 29 The staining with the anti-acetyl-lysine antibody (able to recognize the whole cell acetylation status) confirmed a decreased nuclear expression in the same samples (CRC vs NM: p = 0.03; IDC vs NB: p = 0.05), but also showed an increased cytoplasmic staining in tumors as compared with controls (IDC vs NB: p = 0.03) ( Table 2 , Fig. 2I-L) .
diSCuSSion
This study shows, for the first time, the expression of CPT1A in nuclei of human tumors and cancerous cells. We demonstrate a link between nuclear expression of CPT1, uniquely found in human tumors and neoplastic cells and histone hypoacetylation.
Histone deacetylation is associated with transcriptional repression of genes, as the removal of acetyl groups from lysine residues limits accessibility of the DNA for transcription. 29 The discovery that certain HDAC complexes contained known transcriptional repressors further strengthened the correlations between hypoacetylation and repression. 30 We show that HDAC1 protein interacts with nuclear CPT1 and that treatment with HDAC inhibitors such as sodium-butyrate and TSA affects the nuclear expression of CPT1 in the tumoral cell. Mammalian HDAC1 exists in large multiprotein complex, Sin3. The Sin3 complex contains mammalian (m)Sin3, Sin3-associated proteins of 18 and 30 kDa and retinoblastoma-associated proteins (RbAp)46 and -48. HDAC multiprotein complexes are recruited to specific genomic sites by regulatory proteins. 31 In the nucleus of neoplastic cell, CPT1 could function as a regulatory protein, recruiting HDAC complexes at acetylated histones of specific promoters, to silence genes involved in the control of cancer development by hypoacetylation.
HDAC inhibitors (HDACI) from a number of chemical classes (e.g., short-chain fatty acids like butyrate, isothiocyanates, hydroxamic acid, etc.) have shown promise as anti-cancer agents in animal studies and early clinical trials. [32] [33] [34] [35] In fact, HDACI maintain histones in an acetylated state, and through the resulting alterations in gene regulation, inhibit cell cycle progression, differentiation and in some cases induce apoptosis. 35, 36 Exposure to HDAC inhibitors may also allow reactivation of tumor suppressor genes, silenced by hypoacetylation during tumorigenesis. 36 The use of butyrate to inhibit HDAC1 activity, surprisingly induces, in our model, a decrease of both CPT1 nuclear expression and HDAC1 protein bond to CPT1. Thus, the inhibition of HDAC activity by TSA and butyrate could require the removal of CPT1 from the nucleus of neoplastic cell.
We were able to identify the presence of CPT1A mRNA transcript variant 2 in MCF-7, beside to the classical isoform 1. The mRNA variant 2 codifies for a CPT1A product with a shorter C-terminus. We hypothesize that the shorter CPT1A product could be the one detected in the nucleus of neoplastic cells.
On the other hand, our experiments performed with antiacetyl-lysine antibody show an hyper-acetylation (most likely of non histonic proteins) in the cytoplasm of human tumors, beside a nuclear histone hypo-acetylation. We can speculate that different mechanisms of post-translational regulation of target proteins could be involved in cell growth/death regulation. 36, 37 According to previous data, we confirmed an increase of Fatty Acid Synthase expression in human carcinomas 14, 15 with a corresponding down-regulation of mitochondrial CPT1A. CPT1A inhibition would prevent oxidation of newly synthesized fatty acids.
Nonetheless, the nuclear CPT1 and not the enzyme as one could represent an highly specific target for new more selective and more effective anti-cancer therapies. In fact, drugs suppressing specifically the CPT1 nuclear activity might allow reactivation of tumor suppressors silenced by hypoacetylation, alike molecules who directly inhibit HDAC activity. 1 (lanes 1, 3) , whereas just the neoplastic cells express the CPT1A transcript variant 2 (lanes 2, 4) . Additional amplification of b2 microglobulin (B2M) housekeeping gene allows a semi-quantitative evaluation of PCR products.
